Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.69 USD | +3.12% | +1.91% | -8.64% |
Financials (USD)
Sales 2024 * | 515M | Sales 2025 * | 630M | Capitalization | 3.6B |
---|---|---|---|---|---|
Net income 2024 * | -532M | Net income 2025 * | -457M | EV / Sales 2024 * | 6.34 x |
Net cash position 2024 * | 334M | Net cash position 2025 * | 298M | EV / Sales 2025 * | 5.23 x |
P/E ratio 2024 * |
-6.77
x | P/E ratio 2025 * |
-8.38
x | Employees | 1,276 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.88% |
Latest transcript on Ultragenyx Pharmaceutical Inc.
1 day | +3.12% | ||
1 week | +1.91% | ||
Current month | -6.43% | ||
1 month | -4.71% | ||
3 months | -2.11% | ||
6 months | +31.91% | ||
Current year | -8.64% |
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.21% | 1 M€ | 0.00% | - | |
0.82% | 4 M€ | +20.15% | ||
0.43% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 43.69 | +3.12% | 592,387 |
24-04-19 | 42.37 | -2.33% | 676,054 |
24-04-18 | 43.38 | -1.65% | 768,249 |
24-04-17 | 44.11 | +4.25% | 908,192 |
24-04-16 | 42.31 | -1.31% | 886,829 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.64% | 3.6B | |
+2.49% | 96.73B | |
-0.26% | 21.31B | |
-16.61% | 21.21B | |
-5.57% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |
- Stock Market
- Equities
- RARE Stock